Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …

Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …

N TRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin
receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and …

Background The selective TRK inhibitor larotrectinib was approved for paediatric and adult
patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Resistance to anticancer therapies includes primary resistance, usually related to lack of
target dependency or presence of additional targets, and secondary resistance, mostly …

The proto-oncogene ROS1 encodes a receptor tyrosine kinase with an unknown
physiological role in humans. Somatic chromosomal fusions involving ROS1 produce …

The efficacy of the highly selective RET inhibitor selpercatinib is now established in RET-
driven cancers, and we sought to characterize the molecular determinants of response and …

TRK fusions are oncogenic drivers of various adult and paediatric cancers. The first-
generation TRK inhibitors, larotrectinib and entrectinib, were granted landmark, tumour …

Since the discovery of an oncogenic tropomyosin-receptor kinase (TRK) fusion protein in the
early 1980s, our understanding of neurotrophic tropomyosin-receptor kinase (NTRK) …